Apr 27, 2020

Provention Bio: The First Type 1 Diabetes Breakthrough In 100 Years

Posted by in categories: biotech/medical, innovation

Provention Bio is on track to complete submission of a BLA for its T1D drug Teplizumab by the end of 2020.

This will revolutionise treatment of at-risk T1D patients. The company received the Breakthrough Therapy Designation from FDA.

The company is significantly undervalued on this indication alone — but has enormous potential in other indications.

Comments are closed.